No Data
No Data
Piper Sandler Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Raises Target Price to $16
Fulcrum Therapeutics (FULC) Receives a Buy From Piper Sandler
Census Acquires Fulcrum to Enhance Data Collaboration and Modeling
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter
Is Fulcrum Therapeutics (NASDAQ:FULC) In A Good Position To Deliver On Growth Plans?
Fulcrum Therapeutics (NASDAQ:FULC) Delivers Shareholders Stellar 110% Return Over 1 Year, Surging 27% in the Last Week Alone
JESSE JAMES8832 : might be something
TrytosaveabitOP JESSE JAMES8832: Yup! I will be looking to see where it starts to consolidate over the next couple weeks. Then start scaling in!